Leflunomide Elvim (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo synthesis of pyrimidine nucleotides. By limiting pyrimidine production, the drug suppresses the proliferation of activated T‑cells and B‑cells, thereby decreasing the immune‑driven inflammation that characterises rheumatoid and psoriatic arthritis.

The specific dosage regimen for Leflunomide Elvim is determined by the prescribing physician based on the patient’s clinical condition, disease severity, and laboratory monitoring. Healthcare providers set the appropriate dose and any necessary loading or maintenance schedule.

Leflunomide is classified as contraindicated in pregnancy because it can cause fetal malformations. Women of child‑bearing potential must use effective contraception while on therapy and for a defined wash‑out period after discontinuation. Safety during breastfeeding has not been established, so breastfeeding is generally not recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with conventional DMARDs such as methotrexate, leflunomide offers a once‑daily oral regimen and a distinct mechanism targeting pyrimidine synthesis. It can be used as monotherapy or in combination with other agents, but clinicians must consider its hepatic and hematologic safety profile, which differs from that of methotrexate or sulfasalazine.

Leflunomide Elvim should be stored at temperatures below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Leflunomide Elvim is taken orally, usually as a tablet swallowed whole with water. The exact timing (e.g., with or without food) is guided by the prescribing physician, and patients should follow the dosing instructions provided on the prescription label.

The most serious risks include severe liver injury, bone‑marrow suppression leading to low blood counts, pulmonary toxicity, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver enzymes, complete blood counts, and any respiratory or dermatologic symptoms.

Leflunomide Elvim is contraindicated in patients with severe hepatic impairment, active infections, or known hypersensitivity to leflunomide. It should also be avoided in pregnant women and in women who are not using reliable contraception, as well as in individuals with uncontrolled hypertension or significant bone‑marrow disorders.